Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Posted by Brian Himes on Jun 3rd, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Andrew Callos sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $74.08, for a total value of $1,111,200.00. Following the sale, the executive vice president owned 58,555 shares in the company, valued at approximately $4,337,754.40. This represents a 20.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Callos also recently made the following trade(s):

On Friday, May 1st, Andrew Callos sold 15,857 shares of Cytokinetics stock. The shares were sold at an average price of $65.00, for a total value of $1,030,705.00.
On Thursday, April 30th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $63.26, for a total transaction of $948,900.00.
On Wednesday, April 15th, Andrew Callos sold 7,449 shares of Cytokinetics stock. The stock was sold at an average price of $66.02, for a total transaction of $491,782.98.
On Wednesday, March 18th, Andrew Callos sold 1,930 shares of Cytokinetics stock. The stock was sold at an average price of $62.07, for a total transaction of $119,795.10.
On Tuesday, March 17th, Andrew Callos sold 8,542 shares of Cytokinetics stock. The stock was sold at an average price of $62.15, for a total value of $530,885.30.
On Monday, March 16th, Andrew Callos sold 1,709 shares of Cytokinetics stock. The stock was sold at an average price of $61.03, for a total value of $104,300.27.
On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total value of $156,779.04.
On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.87, for a total value of $1,608,620.00.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $70.91 on Wednesday. The business has a 50 day moving average price of $69.17 and a 200-day moving average price of $65.80. Cytokinetics, Incorporated has a fifty-two week low of $30.81 and a fifty-two week high of $80.20. The firm has a market cap of $8.82 billion, a PE ratio of -10.37 and a beta of 0.42.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. Cytokinetics’s revenue for the quarter was up 1112.5% compared to the same quarter last year. During the same quarter last year, the company posted ($1.36) EPS. Research analysts predict that Cytokinetics, Incorporated will post -6.27 EPS for the current year.

Institutional Trading of Cytokinetics

Several hedge funds have recently modified their holdings of CYTK. Vanguard Group Inc. raised its holdings in Cytokinetics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after buying an additional 191,336 shares during the period. State Street Corp raised its holdings in Cytokinetics by 3.7% during the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after buying an additional 207,961 shares during the period. Deep Track Capital LP raised its holdings in Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after buying an additional 650,000 shares during the period. Geode Capital Management LLC raised its holdings in Cytokinetics by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock valued at $194,214,000 after buying an additional 15,815 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Cytokinetics by 14.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after buying an additional 384,469 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wall Street Zen raised Cytokinetics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Wells Fargo & Company raised their target price on Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Robert W. Baird set a $84.00 target price on Cytokinetics in a research report on Tuesday, March 10th. Royal Bank Of Canada raised their target price on Cytokinetics from $101.00 to $119.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Finally, Truist Financial set a $106.00 target price on Cytokinetics in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $99.30.

Read Our Latest Stock Analysis on CYTK

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.